GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib
Phase 1
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT03398421
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)
Phase 2
Terminated
- Conditions
- Asthma
- Interventions
- Drug: GSK3772847Drug: Placebo
- First Posted Date
- 2018-01-09
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 17
- Registration Number
- NCT03393806
- Locations
- 🇬🇧
GSK Investigational Site, Edgbaston, United Kingdom
A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2017-12-21
- Last Posted Date
- 2021-04-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 437
- Registration Number
- NCT03380429
- Locations
- 🇬🇧
GSK Investigational Site, Harrogate, United Kingdom
Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma
Phase 3
Withdrawn
- Conditions
- Asthma
- Interventions
- Drug: FP/SALDrug: FF/UMEC/VIDrug: TiotropiumDrug: Albuterol/salbutamolDevice: ELLIPTA DPIDevice: Metered Dose InhalerDevice: DISKUS DPIDevice: Connected Inhaler SystemDevice: RESPIMAT inhaler
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT03376932
A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic Cough
- First Posted Date
- 2017-12-13
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 17
- Registration Number
- NCT03372603
- Locations
- 🇬🇧
GSK Investigational Site, North Shields, United Kingdom
BENLYSTA® Special Drug Use Investigation
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2022-11-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 600
- Registration Number
- NCT03370263
- Locations
- 🇯🇵
GSK Investigational Site, Hiroshima, Japan
Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461)
Phase 1
Completed
- Conditions
- HIV InfectionsInfection, Human Immunodeficiency Virus
- Interventions
- Procedure: Blood sampling
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT03368053
- Locations
- 🇧🇪
GSK Investigational Site, Gent, Belgium
The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma
Phase 4
Withdrawn
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2018-01-29
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT03363191
A Clinical Method Development Study to Characterise The Efficacy of a Dentifrice For The Relief Of Dentin Hypersensitivity
Phase 2
Withdrawn
- Conditions
- Dentin Sensitivity
- Interventions
- Drug: Dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 ppm fluoride).Drug: Dentifrice containing 0.454% w/w SnF2 (1100 ppm fluoride).
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT03361774
Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Cachexia
- Interventions
- Drug: Matching PlaceboDrug: GSK2881078
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 97
- Registration Number
- NCT03359473
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath